argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
799.32
-22.81 (-2.77%)
At close: May 15, 2026, 4:00 PM EDT
815.00
+15.68 (1.96%)
After-hours: May 15, 2026, 7:43 PM EDT
argenx SE Revenue
argenx SE had revenue of $1.31B in the quarter ending March 31, 2026, with 62.70% growth. This brings the company's revenue in the last twelve months to $4.75B, up 79.62% year-over-year. In the year 2025, argenx SE had annual revenue of $4.25B with 88.63% growth.
Revenue (ttm)
$4.75B
Revenue Growth
+79.62%
P/S Ratio
10.56
Revenue / Employee
$2,545,609
Employees
1,863
Market Cap
50.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.25B | 2.00B | 88.63% |
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.32M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | 27.09M | 416.32% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.92B |
| Vertex Pharmaceuticals | 12.22B |
| BeOne Medicines AG | 5.70B |
| Incyte | 5.36B |
| Alnylam Pharmaceuticals | 4.29B |
| BioNTech SE | 3.23B |
| Royalty Pharma | 2.44B |
| Moderna | 2.23B |
ARGX News
- 1 day ago - ARGX Maintained by Evercore ISI Group -- Price Target Raised to $1059 - GuruFocus
- 2 days ago - Argenx price target raised to $1,059 from $1,007 at Evercore ISI - TheFly
- 4 days ago - FMR LLC's Strategic Acquisition of Argenx SE Shares - GuruFocus
- 4 days ago - argenx SE at Bank of America Global Healthcare Conference Transcript - GuruFocus
- 4 days ago - argenx SE Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Argenx price target raised to $1,016 from $1,013 at BofA - TheFly
- 6 days ago - Argenx Wins FDA Nod Expanding VYVGART Label To All Adult GMG Patients - Nasdaq
- 7 days ago - argenx (ARGX) Receives FDA Approval for Expanded Vyvgart Label in Myasthenia Gravis - GuruFocus